In total, we performed 58 analyses including comparisons between tumor subtypes (e.g., lung tumors from smokers vs. never-smoking patients), normal and tumor tissues (e.g., normal lung vs. lung tumor tissues), and tumors exhibiting or not a specific somatic mutation (e.g., lung tumors harboring a KRAS mutation vs. lung tumors wild-type for the KRAS gene) (Additional file 2: Table S1). This evidence concerns the gene KRAS and neoplasm.